» Articles » PMID: 29240632

Methods for Sexually Transmitted Disease Prevention Programs to Estimate the Health and Medical Cost Impact of Changes in Their Budget

Overview
Journal Sex Transm Dis
Date 2017 Dec 15
PMID 29240632
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The purpose of this article was to describe methods that sexually transmitted disease (STD) programs can use to estimate the potential effects of changes in their budgets in terms of disease burden and direct medical costs.

Methods: We proposed 2 distinct approaches to estimate the potential effect of changes in funding on subsequent STD burden, one based on an analysis of state-level STD prevention funding and gonorrhea case rates and one based on analyses of the effect of Disease Intervention Specialist (DIS) activities on gonorrhea case rates. We also illustrated how programs can estimate the impact of budget changes on intermediate outcomes, such as partner services. Finally, we provided an example of the application of these methods for a hypothetical state STD prevention program.

Results: The methods we proposed can provide general approximations of how a change in STD prevention funding might affect the level of STD prevention services provided, STD incidence rates, and the direct medical cost burden of STDs. In applying these methods to a hypothetical state, a reduction in annual funding of US $200,000 was estimated to lead to subsequent increases in STDs of 1.6% to 3.6%. Over 10 years, the reduction in funding totaled US $2.0 million, whereas the cumulative, additional direct medical costs of the increase in STDs totaled US $3.7 to US $8.4 million.

Conclusions: The methods we proposed, though subject to important limitations, can allow STD prevention personnel to calculate evidence-based estimates of the effects of changes in their budget.

Citing Articles

An Interactive Modeling Tool for Projecting the Health and Direct Medical Cost Impact of Changes in the Sexually Transmitted Diseases Prevention Program Budgets.

Martin E, Ansari B, Gift T, Johnson B, Collins D, Williams A J Public Health Manag Pract. 2024; 30(2):221-230.

PMID: 38271104 PMC: 11290346. DOI: 10.1097/PHH.0000000000001868.


Building a Simple Model to Assess the Impact of Case Investigation and Contact Tracing for Sexually Transmitted Diseases: Lessons From COVID-19.

Castonguay F, Chesson H, Jeon S, Rainisch G, Fischer L, Adhikari B AJPM Focus. 2023; 3(1):100147.

PMID: 38149077 PMC: 10749878. DOI: 10.1016/j.focus.2023.100147.


Measuring the benefits of occupational safety and health research with economic metrics: Insights from the National Institute for Occupational Safety and Health.

Bushnell P, Pana-Cryan R, Howard J, Quay B, Ray T Am J Ind Med. 2022; 65(5):323-342.

PMID: 35293636 PMC: 10111360. DOI: 10.1002/ajim.23347.


The Estimated Number and Lifetime Medical Cost of HIV Infections Attributable to Sexually Transmitted Infections Acquired in the United States in 2018: A Compilation of Published Modeling Results.

Chesson H, Song R, Bingham A, Farnham P Sex Transm Dis. 2021; 48(4):292-298.

PMID: 33492098 PMC: 10676007. DOI: 10.1097/OLQ.0000000000001358.


The Estimated Direct Lifetime Medical Costs of Sexually Transmitted Infections Acquired in the United States in 2018.

Chesson H, Spicknall I, Bingham A, Brisson M, Eppink S, Farnham P Sex Transm Dis. 2021; 48(4):215-221.

PMID: 33492093 PMC: 10684254. DOI: 10.1097/OLQ.0000000000001380.

References
1.
Peterman T, Toomey K, Dicker L, Zaidi A, Wroten J, Carolina J . Partner notification for syphilis: a randomized, controlled trial of three approaches. Sex Transm Dis. 1997; 24(9):511-8. DOI: 10.1097/00007435-199710000-00003. View

2.
Owusu-Edusei Jr K, Chesson H, Gift T, Tao G, Mahajan R, Ocfemia M . The estimated direct medical cost of selected sexually transmitted infections in the United States, 2008. Sex Transm Dis. 2013; 40(3):197-201. DOI: 10.1097/OLQ.0b013e318285c6d2. View

3.
Golden M, Hogben M, Handsfield H, St Lawrence J, Potterat J, Holmes K . Partner notification for HIV and STD in the United States: low coverage for gonorrhea, chlamydial infection, and HIV. Sex Transm Dis. 2003; 30(6):490-6. DOI: 10.1097/00007435-200306000-00004. View

4.
White P, Ward H, Cassell J, Mercer C, Garnett G . Vicious and virtuous circles in the dynamics of infectious disease and the provision of health care: gonorrhea in Britain as an example. J Infect Dis. 2005; 192(5):824-36. DOI: 10.1086/432004. View

5.
Chesson H, Harrison P, Scotton C, Varghese B . Does funding for HIV and sexually transmitted disease prevention matter? Evidence from panel data. Eval Rev. 2004; 29(1):3-23. DOI: 10.1177/0193841X04270613. View